ERBB2 and breast carcinoma: As a result of this uncertainty, patients with Low-ER HER2-negative breast cancer are commonly excluded from clinical trials available for patients with TNBC despite their shared clinico-pathologic characteristics, chemosensitivity, and prognosis9,11,29.